Non-specific gastric inflammation in children is associated with proton pump inhibitor treatment for more than 6 weeks

Frontiers in Pediatrics

Volumn 2, Issue JAN, 2014, Pages

  Rosas Blum, Eduardo ^a   Tatevian, Nina ^b   Hashmi, Syed Shahrukh ^b   Rhoads, Jon Marc ^b,c   Navarro, Fernando ^b,c  

^a Texas Tech University Health Sciences Center El Paso   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c MEMORIAL HERMANN HOSPITAL   (United States)

Author keywords

Duodenal inflammation; Gastric biopsies; Gastric inflammation; Pediatrics

Indexed keywords

EID: 85030260722     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2014.00003     Document Type: Article

References (24)

1. Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs (2003) 5(1):25-40. doi:10.2165/00148581-200305010-00003
2. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol (2010) 16(19):2323-30. doi:10.3748/wjg.v16.i19.2323
3. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med (2009) 122(10):896-903. doi:10.1016/j.amjmed.2009.04.014
4. Nealis TB, Howden CW. Is there a dark side to long-term proton pump inhibitor therapy? Am J Ther (2008) 15(6):536-42. doi:10.1097/MJT.0b013e31817149bf
5. Lamberts R, Brunner G, Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion (2001) 64(4):205-13. doi:10.1159/000048863
6. Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci (2008) 53(2):385-93. doi:10.1007/s10620-007-9880-7
7. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol (2009) 104(Suppl 2):S27-32. doi:10.1038/ajg.2009.49
8. Drut R, Altamirano E, Cueto Rua E. Omeprazole-associated changes in the gastric mucosa of children. J Clin Pathol (2008) 61(6):754-6. doi:10.1136/jcp.2007.052480
9. Pashankar DS, Israel DM. Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr (2002) 35(5):658-62. doi:10.1097/00005176-200211000-00013
10. Pashankar DS, Israel DM, Jevon GP, Buchan AM. Effect of long-term omeprazole treatment on antral G and D cells in children. J Pediatr Gastroenterol Nutr (2001) 33(5):537-42. doi:10.1097/00005176-200111000-00005
11. Pashankar DS, Bishop WP, Mitros FA. Chemical gastropathy: a distinct histopathologic entity in children. J Pediatr Gastroenterol Nutr (2002) 35(5):653-7. doi:10.1097/00005176-200211000-00012
12. Dohil R, Hassall E, Jevon G, Dimmick J. Gastritis and gastropathy of childhood. J Pediatr Gastroenterol Nutr (1999) 29(4):378-94. doi:10.1097/00005176-199910000-00004
13. Price AB, Misiewicz JJ. Sydney classification for gastritis. Lancet (1991) 337(8734):174. doi:10.1016/0140-6736(91)90836-E
14. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol (1996) 20(10):1161-81. doi:10.1097/00000478-199610000-00001
15. Barron JJ, Tan H, Spalding J, Bakst AW, Singer J. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr (2007) 45(4):421-7. doi:10.1097/MPG.0b013e31812e0149
16. van der Pol RJ, Smits MJ, van Wijk MP, Omari TI, Tabbers MM, Benninga MA. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics (2011) 127(5):925-35. doi:10.1542/peds.2010-2719
17. Aanen MC, Weusten BL, Numans ME, de Wit NJ, Baron A, Smout AJ. Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther (2006) 24(9):1377-84. doi:10.1111/j.1365-2036.2006.03121.x
18. Lee SH, Jang BI, Jeon SW, Kwon JG, Kim EY, Cho KB, et al. A multicenter, randomized, comparative study to determine the appropriate dose of lansoprazole for use in the diagnostic test for gastroesophageal reflux disease. Gut Liver (2011) 5(3):302-7. doi:10.5009/gnl.2011.5.3.302
19. Illueca M, Wernersson B, Henderson C, Lundborg P. Maintenance treatment with proton pump inhibitors for reflux esophagitis in pediatric patients: a systematic literature analysis. J Pediatr Gastroenterol Nutr (2010) 51(6):733-40. doi:10.1097/MPG.0b013e3181e2acfd
20. Kearns GL, Winter HS. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr (2003) 37(Suppl 1):S52-9. doi:10.1097/00005176-200311001-00011
21. Cocanour CS, Dial ED, Lichtenberger LM, Gonzalez EA, Kozar RA, Moore FA, et al. Gastric alkalinization after major trauma. J Trauma (2008) 64(3):681-7. doi:10.1097/TA.0b013e3181641bdb
22. Kato S, Fujimura S, Kimura K, Nishio T, Hamada S, Minoura T, et al. Non-Helicobacter bacterial flora rarely develops in the gastric mucosal layer of children. Dig Dis Sci (2006) 51(4):641-6. doi:10.1007/s10620-006-3185-0
23. Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther (2001) 15(3):379-88. doi:10.1046/j.1365-2036.2001.00888.x
24. Dial EJ, Tran DM, Romero JJ, Zayat M, Lichtenberger LM. A direct role for secretory phospholipase A2 and lysophosphatidylcholine in the mediation of LPS-induced gastric injury. Shock (2010) 33(6):634-8. doi:10.1097/SHK.0b013e3181cb9266